Presenting with an insulin resistant–like pattern,
including beta cell hypersecretion and elevated GIP levels,
nondiabetic antipsychotic-treated patients display emerging
signs of dysmetabolism and a compromised cardiovascular risk
profile. The appetite-regulating hormones GLP-1 and ghrelin
appear not to be influenced by antipsychotic treatment. Our
findings provide new clinical insight into the pathophysiology
associated with metabolic side effects of antipsychotic treatment
and put emphasis on the importance of implementing metabolic
screening into psychiatric practic